Drug Metabolizing Enzymes in Type II Diabetes and their Pharmacogenetics During Therapy of Anti-Diabetes Drugs

Author(s): Chiranjib Chakraborty, Minna J. Hsu, Govindasamy Agoramoorthy.

Journal Name: Current Drug Metabolism

Volume 16 , Issue 10 , 2015


Abstract:

The type 2 diabetes or T2D mellitus has turn into an epidemic throughout the globe in recent years. Various forms of treatment modalities have been available for patients with T2D with some major classes of approved drugs that include Sulfonylureas, Meglitinides, Biguanides, Thiazolidinedione, Alpha-glucosidase inhibitors, GLP-1 analogs, DPP-4 Inhibitors, and SGLT2 inhibitors. This review focuses on the drug metabolizing enzymes (DME), gene polymorphisms, and inter-individual variability in therapeutics including adverse reaction effects involving Phase-I DME and Phase-II in general. This review also covers some key anti-diabetic drugs with respect to their pharcogenomics.

Keywords: Asia, Diabetes, drugs, enzymes, pharcogenomics, T2D.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 16
ISSUE: 10
Year: 2015
Page: [864 - 876]
Pages: 13
DOI: 10.2174/138920021610151210183821
Price: $58

Article Metrics

PDF: 70
HTML: 3